211 related articles for article (PubMed ID: 24253403)
21. Immunogenicity and safety of a pneumococcal conjugate 7-valent vaccine in infants with sickle cell disease.
Reinert P; Benkerrou M; de Montalembert M; Lesprit E; Abadie I; Bernaudin F; Doit C; Bingen E; Tetelboum R; Bonnet E
Pediatr Infect Dis J; 2007 Dec; 26(12):1105-9. PubMed ID: 18043446
[TBL] [Abstract][Full Text] [Related]
22. Pneumococcal Conjugate Vaccine and Clinically Suspected Invasive Pneumococcal Disease.
Palmu AA; Kilpi TM; Rinta-Kokko H; Nohynek H; Toropainen M; Nuorti JP; Jokinen J
Pediatrics; 2015 Jul; 136(1):e22-7. PubMed ID: 26077477
[TBL] [Abstract][Full Text] [Related]
23. A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain.
Asensi F; De Jose M; Lorente M; Moraga F; Ciuryla V; Arikian S; Casciano R; Vento M
Value Health; 2004; 7(1):36-51. PubMed ID: 14720129
[TBL] [Abstract][Full Text] [Related]
24. Invasive Pneumococcal Disease in Patients With Sickle Cell Disease.
Navalkele P; Özgönenel B; McGrath E; Lephart P; Sarnaik S
J Pediatr Hematol Oncol; 2017 Jul; 39(5):341-344. PubMed ID: 28538501
[TBL] [Abstract][Full Text] [Related]
25. Primary Immunization Series Coverage of Children With Sickle Cell Disease.
Peng HK; Dombkowski KJ; Freed GL; Creary SE; Smith D; Reeves SL
Am J Prev Med; 2021 Jul; 61(1):124-127. PubMed ID: 33715942
[TBL] [Abstract][Full Text] [Related]
26. Missed opportunities in antipneumococcal vaccination. Can something more be done for prevention?
Arencibia Jiménez M; Navarro Gracia JF; Delgado de Los Reyes JA; Pérez Torregrosa G; López Parra D; López García P
Arch Bronconeumol; 2014 Mar; 50(3):93-8. PubMed ID: 24315186
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway.
Vestrheim DF; Løvoll O; Aaberge IS; Caugant DA; Høiby EA; Bakke H; Bergsaker MR
Vaccine; 2008 Jun; 26(26):3277-81. PubMed ID: 18456376
[TBL] [Abstract][Full Text] [Related]
28. Maintenance of an Immunogenic Response to Pneumococcal Vaccination in Children With Sickle Cell Disease.
Rahim MQ; Arends AM; Jacob SA
J Pediatr Hematol Oncol; 2022 Jan; 44(1):e51-e55. PubMed ID: 33974588
[TBL] [Abstract][Full Text] [Related]
29. Ambulatory quality indicators to prevent infection in sickle cell disease.
Beverung LM; Brousseau D; Hoffmann RG; Yan K; Panepinto JA
Am J Hematol; 2014 Mar; 89(3):256-60. PubMed ID: 24779032
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
[TBL] [Abstract][Full Text] [Related]
31. Pharmacists as providers: targeting pneumococcal vaccinations to high risk populations.
Taitel M; Cohen E; Duncan I; Pegus C
Vaccine; 2011 Oct; 29(45):8073-6. PubMed ID: 21864625
[TBL] [Abstract][Full Text] [Related]
32. Invasive pneumococcal disease in homozygous sickle cell disease: Jamaican experience 1973-1997.
Knight-Madden J; Serjeant GR
J Pediatr; 2001 Jan; 138(1):65-70. PubMed ID: 11148514
[TBL] [Abstract][Full Text] [Related]
33. 7-valent pneumococcal conjugate vaccine: new preparation. Prevents rare invasive infections in infants.
Prescrire Int; 2002 Feb; 11(57):7-10. PubMed ID: 11985376
[TBL] [Abstract][Full Text] [Related]
34. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine.
Poehling KA; Szilagyi PG; Grijalva CG; Martin SW; LaFleur B; Mitchel E; Barth RD; Nuorti JP; Griffin MR
Pediatrics; 2007 Apr; 119(4):707-15. PubMed ID: 17403841
[TBL] [Abstract][Full Text] [Related]
35. Infant immunisation with a pneumococcal conjugate vaccine: from the age of two months, for all infants.
Prescrire Int; 2006 Dec; 15(86):227-33. PubMed ID: 17167934
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study.
Whitney CG; Pilishvili T; Farley MM; Schaffner W; Craig AS; Lynfield R; Nyquist AC; Gershman KA; Vazquez M; Bennett NM; Reingold A; Thomas A; Glode MP; Zell ER; Jorgensen JH; Beall B; Schuchat A
Lancet; 2006 Oct; 368(9546):1495-502. PubMed ID: 17071283
[TBL] [Abstract][Full Text] [Related]
37. Carriage of Streptoccoccus pneumoniae 7 years after implementation of vaccination program in a population with very high and long-lasting coverage, Italy.
Ansaldi F; de Florentiis D; Canepa P; Zancolli M; Martini M; Orsi A; Durando P; Icardi G
Vaccine; 2012 Mar; 30(13):2288-94. PubMed ID: 22306795
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
[TBL] [Abstract][Full Text] [Related]
39. Predictors for bacteremia in febrile sickle cell disease children in the post-7-valent pneumococcal conjugate vaccine era.
Chang TP; Kriengsoontorkij W; Chan LS; Wang VJ
J Pediatr Hematol Oncol; 2013 Jul; 35(5):377-82. PubMed ID: 23588338
[TBL] [Abstract][Full Text] [Related]
40. Pneumococcal polysaccharide immunization of children with sickle cell disease. II. Serologic response and pneumococcal disease following immunization.
Overturf GD; Selzer JW; Chan L; Weiss J; Field R; Rigau-Perez JG; Powars D; Uy C; Pang EJ; Honig G; Steele R; Edmonds R; Portnoy B
Am J Pediatr Hematol Oncol; 1982; 4(1):25-35. PubMed ID: 7091574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
